226 related articles for article (PubMed ID: 26370136)
1. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
3. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
4. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
9. Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni H; Soe Z; Moe S
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E
Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
[TBL] [Abstract][Full Text] [Related]
11. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
Zou Y; Xiao J; Yang DH; Li J; Chen Q
COPD; 2016 Aug; 13(4):499-508. PubMed ID: 26846588
[TBL] [Abstract][Full Text] [Related]
14. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
17. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
Wise RA; Chapman KR; Scirica BM; Bhatt DL; Daoud SZ; Zetterstrand S; Reisner C; Gil EG
JAMA; 2019 May; 321(17):1693-1701. PubMed ID: 31063575
[TBL] [Abstract][Full Text] [Related]
18. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Manoharan A; Morrison AE; Lipworth BJ
Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
[TBL] [Abstract][Full Text] [Related]
19. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
Beeh KM; Watz H; Puente-Maestu L; de Teresa L; Jarreta D; Caracta C; Garcia Gil E; Magnussen H
BMC Pulm Med; 2014 Dec; 14():209. PubMed ID: 25539654
[TBL] [Abstract][Full Text] [Related]
20. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
Maltais F; Milot J
Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
